We interviewed Tim Moore, CEO of HAVN Life Sciences (CSE: HAVN) (OTC: HAVLF) regarding his firm’s recent acquisition of Spore Life Sciences.
Tim shared the strategy behind the acquisition and the resulting synergies; new opportunities and products within their distribution network. He also added colour to the functional mushroom competitive landscape and described the rapid growth of the market.
This is a lucrative acquisition for HAVN Life, as the agreement meets many of their objectives at once including acquiring a revenue generating business, market expansion and a short pathway to profitability in the near future. Read our full analysis here.
The opinions provided in this article are those of the author and do not constitute investment advice. Readers should assume that the author and/or employees of Capital 10X hold positions in the company or companies mentioned in the article. For more information, please see our Content Disclaimer.